Evaluation of the Anticancer and DNA-Binding Characteristics of Dichloro(diimine)zinc(II) Complexes

Bandar A. Babgi 1,* , Doaa Domyati 2 , Magda H. Abdellattif 3 and Mostafa A. Hussien 1,4

Abstract: Several metal diimine complexes have been reported to possess anticancer properties. To evaluate the anticancer properties of tetrahedral zinc(II) diimine complexes, six complexes were synthesized with the general formula M(N\textsuperscript{2+})Cl\textsubscript{2} {where M = Zn, Pt and N\textsuperscript{2+} = 2,2'-biquinoline (1), 2,2'-dipyridylketone (2) and 4-((pyridine-2-ylmethylene)amino)phenol (3)}. In general, the intrinsic DNA-binding constants for the different compounds exhibited values within close proximity; the changes in the viscosity of the CT-DNA upon binding to the compounds suggest intercalation-binding mode. Molecular docking study predicted that complexes containing the highly planar ligand 2,2'-biquinoline are capable to establish \(\pi-\pi\) interactions with nucleobases of the DNA; the other four complexes engaged in donor–acceptor interactions with DNA nucleobases. The six complexes and two reference drugs (cisplatin and sunitinib) were tested against two cancer cell lines (COLO 205 and RCC-PR) and one normal cell line (LLC-MK2), highlighting the better performance of the zinc(II) complexes compared to their platinum(II) analogues. Moreover, zinc(II) complexes have higher selectivity index values than the reference drugs, with promising anticancer properties.

Keywords: zinc(II); diimine; DNA-binding; anticancer properties; molecular docking

1. Introduction

Cisplatin (cis-diaminedichloridoplatinum(II)), carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)) and oxaliplatin (trans-R,R-cyclohexane-(1,2-diamine)oxalatoplatinum(II)) are clinically approved metal-based drugs used for the chemotherapeutic treatment of several cancer types [1]. Pt(II) drugs are believed to be activated by the hydrolysis of anionic ligands and the aqua-adducts bind to DNA, cross-linking the DNA strands; this process leads to block replication and prevents transcription [2]. Although platinum-based complexes possess excellent anticancer properties, there are several problems associated with them, including sever side-effects (e.g., nausea and kidney toxicity) and acquired resistance developed by some tumor types [3–5]. These drawbacks motivate further research to synthesize other transition metal complexes that exhibit comparable anticancer properties to that of cisplatin, with fewer side-effects. Several metal complexes have been tested for their antitumor properties, especially metal complexes employing derivatives of 2,2’-bipyridines or 1,10-phenanthrolines as ligands [6,7]. The interest in this type of ligands is due to their ability to interact non-covalently with various biomolecules [8–10]. Among diimine complexes, vanadium diimine complexes have received considerable attention. Metvan is a peroxovanadium compound (1 in Figure 1), which induces apoptosis in cancer cell lines and exhibits considerable anticancer activity against human glioblastoma (GBM) and breast cancer xenograft models.
Some examples of reported polypyridyl metal complexes with potential anticancer activities.

Figure 1. Some examples of reported polypyridyl metal complexes with potential anticancer activities.

Zinc is an essential trace element for human nutrition and is a vital part of many enzymes, including DNA polymerase complexes [25]. In some studies, zinc supplementation exhibited inhibition of the proliferation of esophageal carcinoma cells [26,27]. Zinc(II) complexes containing polydentate Schiff bases showed promising anticancer properties [28].
Many thiosemicarbazone-containing ligands have been utilized in synthesizing Zn(II) complexes with inhabitation capabilities against several cancer cell lines [29–31]. However, tetrahedral zinc diimine complexes have scarcely been examined. The objective of the current work is to highlight the DNA-binding behavior and anticancer properties of a range of zinc(II) complexes with the general formula [ZnCl₂(diimine)]. This class of complexes has structural flexibility by increasing the coordination number from four to six. Parallel examination of the DNA-binding and anticancer activities of the analogue PtCl₂(diimine) complexes would allow the initial evaluation the role of the zinc(II).

2. Materials and Methods

2.1. Materials

All reactions were performed in oven-dried glassware using the standard Schlenk technique under an inert gas atmosphere, and performed utilizing solvents dried over A4 molecular sieves. All reagents were obtained commercially and used as received without further purification. All chemicals were purchased from Sigma Aldrich and used without further purification. The Schiff base ligand 4-((pyridine-2-ylmethylene)amino)phenol (L) was synthesized according to a previously reported procedure [32]. ZnCl₂(2,2’-biquinoline) (Zn-1), ZnCl₂(2,2’-dipyridylketone) (Zn-2) and ZnCl₂(L) (Zn-3) (Figure 2) were synthesized by refluxing equimolar amounts of ZnCl₂ and the ligands in absolute ethanol (minimum amounts of chloroform could be used to solubilize the ligand in the reaction mixture). The products were precipitated form the reaction mixture in a few minutes. PtCl₂(2,2’-biquinoline) (Pt-1), PtCl₂(2,2’-dipyridylketone) (Pt-2) and PtCl₂(L) (Pt-3) (Figure 2) were synthesized by stirring equimolar amounts of PtCl₂(dmso)₂ and the ligands in dichloromethane. The products were precipitated by the addition of diethylether. 

1H NMR data of the complexes are available in the supporting information (Figures S1–S6). Full characterizations and detailed procedures are presented in previously published works [32–37].

2.2. Methods and Instrumentation

Electronic absorption spectroscopy was collected using a Genesys-10s UV-VIS spectrophotometer and 1 cm path-length quartz cells; bands are reported in the form wavelength (nm). 1H NMR (850 MHz) spectra were obtained in DMSO-D₆ solutions using a Bruker Avance 850 MHz spectrometer.

2.3. DNA Binding Studies

Absorption spectra of the CT-DNA in the presence of different compounds were recorded, subtracting the compound absorption. Six solutions in 5 mM Tris-HCl (pH = 7.4) and 50 mM NaCl were synthesized by maintaining the CT-DNA at 20 µM (5% v/v DMSO was used to support the solubility of the complexes in aqueous media) and
varying the ratio of [compounds]/[CT-DNA] (from 0 to ~0.1). The quantitative affinities of the compounds toward CT-DNA are expressed in terms of the intrinsic-binding constant ($K_b$), which can be calculated from the Benesi–Hildebrand equation:

$$\frac{[\text{compound}]}{(\varepsilon_A - \varepsilon_F)} = \frac{[\text{compound}]}{(\varepsilon_B - \varepsilon_F)} + \frac{1}{K_b} (\varepsilon_B - \varepsilon_F)$$  \hspace{1cm} (1)

where $\varepsilon_A$, $\varepsilon_B$ and $\varepsilon_F$ correspond to the extinction coefficient for the CT-DNA at the specific addition of the compound, before the addition of the compound, and at the fully bound mode, respectively. From the plotting of $[\text{compound}]/(\varepsilon_A - \varepsilon_F)$ versus $[\text{compound}]$, $K_b$ is obtainable by dividing the slope on the intercept [38]. The viscosity measurements were established by utilizing an Ostwald viscometer. The mode of binding of each complex was evaluated by micro-additions (10 µL) of the complex to a CT-DNA/buffer solution while maintaining the [complex]/[DNA] ratio in the range 0.02 to 0.2. The solutions were allowed to stand for 15 min at 25 °C in a water bath before measurements. The flow times of each addition to the solutions were recorded and replicated four times. The relative viscosity ($\eta/\eta_o)^{1/3}$ values were plotted against [complex]/[DNA], where $\eta_o$ and $\eta$ represent the specific viscosity of the CT-DNA and the CT-DNA-complex adduct, respectively. The specific viscosity values, $\eta$ and $\eta_o$, were obtained using the formulation $[(t - t_b)/t_b]$, where $t$ is the observed flow time and $t_b$ is the buffer flow time [38,39].

2.4. Molecular Docking Studies

Molecular docking simulations were performed in the Molecular Operating Environment (MOE) 2008.10 (Chemical Computing Group Inc., Montreal, QC, Canada, 2008). The docking scores were attained in two steps: using the London dG scoring function in MOE software; and improved utilizing two unrelated refinement methods. To confirm that the refined poses of the complexes were of acceptable geometry, Grid min pose and Force-field were employed. Bond rotations were restricted to avoid changes in the geometry while examining the best five binding positions. To evaluate the binding free energy of the compounds against DNA, docking was performed for positions of the complexes and the co-crystallized structure of the B-DNA (RSCP PDB code: 1BNA); RMSD values were employed to assess the best binding position.

2.5. Anticancer Activity and Cytotoxicity

The cells were sourced from the Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt. The cells were maintained in the tissue culture unit and grown in RBMI-1640 medium, supplemented with 10% heat-inactivated FBS, 50 units/mL of penicillin and 50 mg/mL of streptomycin, maintaining them in a humidified atmosphere containing 5% CO$_2$ [40,41]. Serial sub-culturing was used to keep the cells as a monolayer culture. Cell culture reagents were sourced from Lonza (Basel, Switzerland). The antitumor properties of the examined complexes were assessed against COLO 205 [colon cancer], RCC-PR [kidney cancer], and LLC-MK2 [normal] cell lines. Cytotoxicity was identified using the sulforhodamine B (SRB) assay method, as described in the literature [42]. Exponentially growing cells were gathered, employing 0.25% Trypsin–EDTA, and seeded in 96-well plates at 1000–2000 cells/well in RBMI-1640-supplemented medium for 24 h. Cells were incubated for 72 h with various concentrations of the examined compounds in DMSO. Then, the cells were set up with 10% trichloroacetic acid for 1 h at 4 °C. Wells were stained for 10 min at ambient temperature with 0.4% SRBC (Sulphorhodamine B) dissolved in 1% CH$_3$COOH. After drying the plates in air for 24 h, the dye was solubilized with Tris-HCl for 5 min on a shaker at 1600 rpm. The optical density (OD) of each well was quantified spectrophotometrically at 564 nm with an ELISA microplate reader (ChroMate-4300, FL, USA). The minimum inhibitory concentration (IC$_{50}$) values were evaluated according to the equation for the Boltzmann sigmoidal concentration response curve using the nonlinear regression fitting models (Graph Pad, Prism Version 9).
3. Results
3.1. DNA-Binding Studies

The current study was undertaken to evaluate the DNA-binding capabilities of tetrahedral zinc(II) diimine. Analogue platinum(II) complexes were tested as benchmarks, motivated by the fact that several platinum(II) complexes are known for their strong antitumor activities originating from targeting DNA. The insolubility of our complexes in aqueous medium necessitated the use of minimum amounts of DMSO to prepare solutions for biological studies. The stabilities of our complexes in DMSO and DMSO-buffer mixture are important for their biological applications. Tetrahedral zinc(II) complexes are quite labile and can undergo ligand substitution. Hence, their stabilities were justified in DMSO and D$_2$O/DMSO mixtures over time. Specifically, $^1$H NMR data for all the complexes were collected after 72 h in DMSO and in D$_2$O/DMSO, without any indication of degradation. However, Zn-3 and Pt-3 showed signs of hydrolysis after 24 h on the Schiff base ligand, but the hydrolysis products were estimated to be around 8% over 72 h, as illustrated in Figure 3. Further confirmation was attained by measuring the conductivity of the complexes in DMSO and DMSO/H$_2$O; no conductivity was observed, which demonstrates there was no chloro/solvent exchange.

Upon the titration process described in the experimental section, spectroscopic changes in the absorption band of CT-DNA at ca. 270 nm were used to determine intrinsic-binding constants ($K_b$) of the complexes (Figure 4). The binding affinities provide information on the strength of the interaction with DNA, resulting from the different interaction modes (Table 1). In general, the binding affinities of the zinc complexes and their analogue platinum complexes were within a narrow range, highlighting their strong binding to CT-DNA. Apparently, the tetrahedral geometry of zinc(II) does not causing any notable steric hinderance, which explains the proximity of the results to those of square planar analogue platinum(II) complexes. The best binding affinities were obtained for Zn-1 and Pt-1, which contain the 2,2'-biquinoline ligand, which has the capability to establish $\pi-\pi$
interactions with nucleobases of the DNA; the binding constants for most of our complexes were within the range of classical intercalators \(10^4\text{–}10^7\) [20,43,44].

Figure 4. Changes in the electronic spectra of CT-DNA after increased concentrations of Zn-1 (blue spectrum/0.6 \(\mu\)M, grey spectrum/1.3 \(\mu\)M, green spectrum/1.9 \(\mu\)M, black spectrum/2.6 \(\mu\)M and red spectrum/3.2 \(\mu\)M) and the plotting of \([\text{Zn-1}] / [\varepsilon_A - \varepsilon_F]\) against \([\text{Zn-1}]\) to determine the binding affinity.

Table 1. DNA-binding affinities \(K_b\) toward ct-DNA obtained from spectroscopic titration and docking scores obtained by MOE.

| Compound | \(K_b\) (Intrinsic Binding Constant) | Docking Scores | Proposed Interaction by Docking |
|----------|--------------------------------------|----------------|---------------------------------|
| Zn-1     | \(6.67 \times 10^6\)                | \(-3.45\)      | H-\(\pi\) (G\(16\)–biquinoline) |
| Pt-1     | \(4.44 \times 10^6\)                | \(-3.34\)      | H-\(\pi\) (A\(17\)–biquinoline) |
| Zn-2     | \(5.00 \times 10^5\)                | \(-4.78\)      | H-acceptor (G\(9\)–dipyridylketone) |
| Pt-2     | \(1.00 \times 10^5\)                | \(-5.52\)      | H-acceptor (G\(14\)–dipyridylketone) |
| Zn-3     | \(1.00 \times 10^5\)                | \(-5.42\)      | H-acceptor (G\(16\)–Cl) |
| Pt-3     | \(5.00 \times 10^5\)                | \(-4.58\)      | None |

The trend in the changes in viscosity of DNA upon interacting with a compound can indicate its mode of interaction with DNA. If the compound interacts electrostatically, no change in the relative viscosity of the DNA solution would be observed [32]. In a similar manner, groove-binder compounds do not affect the relative viscosity of the DNA. In contrast, intercalating compounds produce an elongation of the DNA polymer, leading to an increase in relative viscosity [39]. Partial intercalators cause kinking of the DNA chain, which decreases the relative viscosity [45]. Similarly, molecule binding covalently decrease the relative viscosity of the DNA solution by unwinding the DNA double-helix [46]. Therefore, viscosity measurements were performed for our complexes and ethidium bromide (as a positive control) to identify the modes of binding (Figure 5). From the trends in the changes in the relative viscosity, all the complexes induced an increase in the relative viscosity of CT-DNA, which suggests their binding via intercalation. However, the increase in the relative viscosity of CT-DNA seems to be ligand-dependent (Figure 5). The highly \(\pi\)-delocalized planar ligand (2,2'-biquinoline) induced the strongest increase in the relative viscosity compared to the other ligands, whereas the impact of the metal fragment was negligible.
3.2. Docking Studies

Docking studies were directed to identify the possible sites and the possible modes of interactions, to aid rationalizing the binding information obtained by the DNA-binding measurements. A cartoon representation of the docked B-DNA is illustrated in Figure 6, with approximate binding sites of Zn-1, Zn-2, Zn-3, Pt-1, Pt-2, and Pt-3 as obtained by the docking study, showing that all the studied complexes intercalated in the major groove. The binding scores are listed in Table 1; the docking scores for 2,2′-biquinoline complexes showed that Zn-1 has a higher score than that of Pt-1, which is in agreement with the experimentally measured binding affinities. Docking modelling suggests that Zn-1 can establish π–H interactions with guanine (G_{16}) and adenine (A_{17}), whereas Pt-1 does not show any notable stacking interaction by docking, due to the slight out-of-plane twist caused by the steric hinderance (hydrogens of the biquinoline with the chloro ligands). For the ligand 2,2′-dipyridylketone, the presence of the carbonyl group allows the ligand to establish hydrogen bonding with the nucleobases. Zn-2 forms a hydrogen bond with N2 in guanine (G_{10}), whereas Pt-2 forms it with N2 in guanine (G_{14}). The slight difference in the position is due to the difference in geometrical structure between the two complexes. Zn-3 and Pt-3 bind to B-DNA in almost the same position; however, Zn-3 establishes a hydrogen–acceptor interaction.

![Figure 5](image1.png)

**Figure 5.** Changes in the relative viscosity of CT-DNA upon the addition of the different zinc(II) complexes.

![Figure 6](image2.png)

**Figure 6.** The sequence of B-DNA used in the docking, highlighting the binding site of all the complexes and 3D representations of compound–DNA adducts.

3.3. Anticancer Activities

The aim of the current study was to explore the potential of dichloro(diimine)zinc(II) in chemotherapy in comparison to dichloro(diimine)platinum(II) complexes. The complexes were examined against human colon adenocarcinoma (COLO 205) and human
kidney clear cell carcinoma (RCC-PR) cancer cell lines, as well as a normal rhesus monkey kidney epithelial (LLC-MK2) cell line. Cisplatin and sunitinib were chosen as benchmark drugs; cisplatin is structurally relevant to the currently studied compounds, whereas sunitinib is an effective drug for treating kidney cancer. Scanning through the minimum inhibitory concentration (IC\textsubscript{50}) values (Table 2), zinc complexes have much lower cytotoxicity than their platinum analogues and cisplatin against COLO 205; however, their cytotoxicity is similar to that of sunitinib. Zinc complexes have slightly lower cytotoxicity than their platinum analogues, but their IC\textsubscript{50} values are 20% to 40% higher than that of cisplatin, and 50% to 75% higher than that of sunitinib. The cytotoxicity of the zinc complexes towards the normal cell line was lower than that of their platinum counterparts, cisplatin and sunitinib. The selectivity index (SI) was calculated according to the equation (SI = IC\textsubscript{50} against normal cell line ÷ IC\textsubscript{50} against cancer cell lines) [47]: SI values were in the range 40–77 for zinc complexes, whereas it was in the range 20–32 for platinum complexes. Compared to cisplatin (SI = ~32) and sunitinib (SI = ~60), zinc complexes have comparable or better selectivity toward cancer cell lines over normal cell lines.

Table 2. Minimum inhibitory concentrations (IC\textsubscript{50}) of the different compounds and reference drugs against COLO 205, RCCD-PR and LLC-MK2 cell lines.

| Compound | COLO 205 | RCC-PR | LLC-MK2 |
|----------|----------|--------|---------|
| Zn-1     | 9.46 ± 0.02 | 15.54 ± 0.77 | 695.37 ± 42.89 |
| Pt-1     | 21.43 ± 0.04 | 17.81 ± 0.14 | 453.77 ± 6.99 |
| Zn-2     | 8.10 ± 0.08 | 14.41 ± 0.10 | 627.17 ± 37.36 |
| Pt-2     | 14.82 ± 0.06 | 18.69 ± 0.04 | 397.30 ± 12.26 |
| Zn-3     | 8.18 ± 0.01 | 13.54 ± 0.03 | 534.37 ± 37.23 |
| Pt-3     | 14.69 ± 0.02 | 15.47 ± 0.04 | 472.87 ± 17.81 |
| Cisplatin| 12.59 ± 0.04 | 11.07 ± 0.07 | 37.50 ± 31.84 |
| Sunitinib| 9.22 ± 0.01 | 8.74 ± 0.04 | 548.13 ± 61.18 |

4. Conclusions

Several metal diimine complexes have been reported to exhibit anticancer properties. Our current work was dedicated to exploring the potential of tetrahedral zinc(II) diimine complexes in chemotherapy. Studies have suggested that the tetrahedral structure of zinc(II) is more favored in biological systems than octahedral structures [48]. Three dichloro(diimine)zinc(II) and platinum(II) complexes were synthesized. In general, the DNA-binding properties, as expressed by the intrinsic binding constants of the zinc(II) complexes and their analogue platinum(II) complexes, are within a narrow range, highlighting their strong binding to CT-DNA by intercalation. Apparently, the tetrahedral geometry of the zinc(II) and square planar geometry of platinum(II) are sterically similar which explain the proximity of the results. As expected, the highly planar ligand 2,2'-biquinoline produces complexes with high capability to establish π-π interactions with nucleobases of the DNA and cause optimum binding conditions. The six complexes and two reference drugs (cisplatin and sunitinib) were examined against two cancer cell lines and one normal cell line; zinc(II) complexes showed better anticancer properties than their platinum(II) counterparts. Moreover, zinc(II) complexes have comparable cytotoxicity to and higher selectivity index values than the reference drugs. The current study highlights the strong potential of tetrahedral zinc(II) complexes for cancer treatment, which could motivate further research in the near future to identify their mechanisms of action.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/chemistry3040086/s1, \textsuperscript{1}H NMR data (Figures S1–S6); IR data (Figures S7–S12); DNA–compound titration curves to obtain binding affinities of the compounds toward ct-DNA (Figures S13–S17); 2D illustrations of interactions of different compounds with B-DNA as predicted by MOE (Figures S18 and S19).
Author Contributions: Conceptualization, B.A.B.; Data curation, D.D. and M.H.A.; Formal analysis, D.D., M.H.A. and M.A.H.; Funding acquisition, B.A.B.; Investigation, B.A.B., D.D., M.H.A. and M.A.H.; Methodology, B.A.B., M.H.A. and M.A.H.; Project administration, B.A.B.; Resources, B.A.B.; Software, M.H.A. and M.A.H.; Supervision, B.A.B.; Visualization, B.A.B. and M.A.H.; Writing—Original draft, B.A.B.; Writing—Review and editing, B.A.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: The data presented in this study are available on request from the authors.

Acknowledgments: B.A.B. and M.A.H. would like to thank K.A.U. technical and financial support.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation          | Description                                          |
|-----------------------|------------------------------------------------------|
| CT-DNA                | calf-thymus DNA                                      |
| COLO 205              | human colon adenocarcinoma cancer cell line          |
| RCC-PR                | human kidney clear cell carcinoma cancer cell line   |
| LLC-MK2               | rhesus monkey kidney epithelial normal cell line     |

References

1. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov.* 2005, 4, 307–320. [CrossRef]
2. Pasetto, L.M.; Andrea, M.R.D.; Brandes, A.A.; Rossi, E.; Monfardini, S. The development of platinum compounds and their possible combination. *Crit. Rev. Oncol. Hematol.* 2006, 60, 59–75. [CrossRef]
3. Wong, E.; Giandomenico, C.M. Current Status of Platinum-Based Antitumor Drugs. *Chem. Rev.* 1999, 99, 2451–2466. [CrossRef]
4. Rabik, C.A.; Dolan, M.E. Mechanisms of resistance and toxicity associated with platinating agents. *Cancer Treat. Rev.* 2007, 33, 9–23. [CrossRef]
5. Heffeter, P.; Jungwirth, U.; Jakupec, M.; Galanski, M.; Elbling, L.; Micksche, M.; Keppler, B.; Berger, W. Resistance against novel anticancer metal compounds: Differences and similarities. *Drug Resist. Updates* 2008, 11, 1–16. [CrossRef]
6. Schatzschneider, U. Chapter 14: Metallointercalators and metalloinsertors: Structural requirements for DNA recognition and anticancer activity. In *Metallo-Drugs: Development and Action of Anticancer Agents*; Sigel, A., Sigel, H., Freisinger, E., Sigel, R.K.O., Eds.; De Gruyter: Berlin, Germany; Boston, MA, USA, 2018; pp. 387–436.
7. Pages, B.J.; Ang, D.L.; Wright, E.P.; Aldrich-Wright, J.R. Metal complex interactions with DNA. *Dalton Trans.* 2015, 44, 3505–3526. [CrossRef]
8. Lo, K.K.-W. Luminescent Rhenium (I) and Iridium (III) Polypyridine Complexes as Biological Probes, Imaging Reagents, and Photocytotoxic Agents. *Acc. Chem. Res.* 2015, 48, 2985–2995. [CrossRef] [PubMed]
9. Sullivan, M.P.; Holtkamp, H.U.; Meier, S.M.; Hartinger, C.G. Chapter 10: The Analysis of Therapeutic Metal Complexes and Their Biomolecular Interactions. In *Inorganic and Organometallic Transition Metal Complexes with Biological Molecules and Living Cells*; Lo, K.K.-W., Ed.; Academic Press: Cambridge, MA, USA, 2017; pp. 355–386.
10. Simpson, D.H.; Scott, P. Chapter 7: Antimicrobial Metallodrugs. In *Inorganic and Organometallic Transition Metal Complexes with Biological Molecules and Living Cells*; Lo, K.K.-W., Ed.; Academic Press: Cambridge, MA, USA, 2017; pp. 205–243.
11. D’Cruz, O.J.; Uckun, F.M. Metvan: A novel oxovanadium (IV) complex with broad spectrum anticancer activity. *Expert. Opin. Investig. Drugs* 2002, 11, 1829–1836. [CrossRef] [PubMed]
12. Scrivens, P.J.; Alalou-Jamali, M.A.; Giannini, G.; Wang, T.; Loignon, M.; Batist, G.; Sandor, V.A. Ccd25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. *Mol. Cancer Ther.* 2003, 2, 1053–1059. [PubMed]
13. Zhang, S.; Zhu, Y.; Tu, C.; Wei, H.; Yang, Z.; Lin, L.; Ding, J.; Zhang, J.; Guo, Z. A novel cytotoxic ternary copper (II) complex of 1,10-phenanthroline and l-threonine with DNA nuclease activity. *J. Inorg. Biochem.* 2004, 98, 2099–2106. [CrossRef] [PubMed]
14. Rajendiran, V.; Karthik, R.; Palaniandavar, M.; Stoeckli-Evans, H.; Periasamy, V.S.; Akbarsha, M.A.; Srinag, B.S.; Krishnamurthy, H. Mixed-ligand copper (II)-phenolate complexes: Effect of coligand on enhanced DNA and protein binding, DNA cleavage, and anticancer activity. *Inorg. Chem.* 2007, 46, 8208–8221. [CrossRef] [PubMed]
15. Nagababu, P.; Barui, A.K.; Thulasiraman, B.; Devi, C.S.; Satyanarayana, S.; Patra, C.R.; Sreedhar, B. Antiangiogenic Activity of Mononuclear Copper (II) Polyoxometalyl Complexes for the Treatment of Cancers. *J. Med. Chem.* 2015, 58, 5226–5241. [CrossRef]
16. Mashat, K.; Babgi, B.A.; Hussien, M.A.; Arshad, M.N.; Abdellatif, M. Synthesis, structures, DNA-binding and anticancer activities of some copper(I)-phosphate complexes. *Polyhedron* 2019, 158, 164–172. [CrossRef]
17. Babgi, B.A.; Mashat, K.H.; Abdellatif, M.H.; Arshad, M.N.; Alzahrani, K.A.; Asiri, A.M.; Du, J.; Humphrey, M.G.; Hussien, M.A. Synthesis, structures, DNA-binding, cytotoxicity and molecular docking of CuBr (PPh3)(diimine). *Polyhedron* 2020, 192, 114847. [CrossRef]
18. Alsaedi, S.; Babgi, B.A.; Abdellatif, M.H.; Arshad, M.N.; Emwas, A.; Jaremko, M.; Humphrey, M.G.; Asiri, A.M.; Hussein, M.A. DNA-Binding and Cytotoxicity of Copper(II) Complexes Containing Functionalized Dipyridylphenazine Ligands. *Pharmaceutics* 2021, 13, 764. [CrossRef]

19. Mital, M.; Ziora, Z. Biological applications of Ru (II) polypyridyl complexes. *Coord. Chem. Rev.* 2018, 375, 434–458. [CrossRef]

20. Li, X.; Gorle, A.K.; Sundaraneedi, M.K.; Keene, F.R.; Collins, J.G. Kinetically-inert polypyridylruthenium (II) complexes as therapeutic agents. *Coord. Chem. Rev.* 2018, 375, 134–147. [CrossRef]

21. Kapdi, A.R.; Fairlamb, I.J.S. Anti-cancer palladium complexes: A focus on PdX2L2, palladacycles and related complexes. *Chem. Soc. Rev.* 2014, 43, 4751–4777. [CrossRef]

22. Darabi, F.; Hadadzadeh, H.; Simpson, J.; Shahpiri, A. A water-soluble Pd(ii) complex with a terpyridine ligand: Experimental and molecular modeling studies of the interaction with DNA and BSA; and in vitro cytotoxicity investigations against five human cancer cell lines. *New J. Chem.* 2016, 40, 9081–9097. [CrossRef]

23. Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. *Coord. Chem. Rev.* 2007, 253, 1670–1681. [CrossRef]

24. Messeri, L.; Abbate, F.; Marcon, G.; Orioli, P.; Fontani, M.; Mini, E.; Mazzei, T.; Carotti, S.; O’Connell, T.; Zanello, P. Gold (III) Complexes as Potential Antitumor Agents: Solution Chemistry and Cytotoxic Properties of Some Selected Gold (III) Compounds. *J. Med. Chem.* 2000, 43, 3541–3548. [CrossRef] [PubMed]

25. Markov, D.; Naryshkina, T.; Mustaev, A.; Severinov, K. A zinc-binding site in the largest subunit of DNA-dependent RNA polymerase is involved in enzyme assembly. *Genes Dev.* 1999, 13, 2439–2448. [CrossRef] [PubMed]

26. Choi, S.; Cui, C.; Luo, Y.; Kim, S.H.; Ko, J.K.; Huo, X.; Ma, J.; Fu, L.W.; Souza, R.F.; Korichneva, I.; et al. Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1. *FASEB J.* 2018, 32, 404–416. [CrossRef] [PubMed]

27. Fong, L.Y.; Nguyen, VT.; Farber, J.L. Esophageal cancer prevention in zinc-deficient rats: Rapid induction of apoptosis by replenishing zinc. *J. Natl. Cancer Inst.* 2001, 93, 1525–1533. [CrossRef]

28. Asadizadeh, S.; Amirnasr, M.; Tiran, F.F.; Mansouri, A.; Schenk, K. DNA-BSA interaction, cytotoxicity and molecular docking of mononuclear zinc complexes with reductively cleaved N2S2 Schiff base ligands. *Inorg. Chem. Acta.* 2018, 483, 310–320. [CrossRef]

29. Vikneswaran, R.; Eltayeb, N.E.; Ramesh, S.; Yahya, R. New alicyclic thiosemicarbazone chelated zinc (II) antitumor complexes: Interactions with DNA/protein, nuclease activity and inhibition of topoisomerase-I. *Polyhedron* 2016, 105, 89–95. [CrossRef]

30. Kovala-Demertzi, D.; Yadav, P.N.; Wiecek, J.; Skoulika, S.; Varadinova, T.; Demertzis, M.A. Zinc (II) complexes derived from (2,2’-Biquinoline-κ2N,N’)-dichloropalladium(II), -copper(II) and -zinc(II). *Inorg. Chem.* 2006, 105, 1558–1567. [CrossRef]

31. Markov, D.; Naryshkina, T.; Mustaev, A.; Severinov, K. A zinc-binding site in the largest subunit of DNA-dependent RNA polymerase is involved in enzyme assembly. *Genes Dev.* 1999, 13, 2439–2448. [CrossRef] [PubMed]
44. Barone, G.; Terenzi, A.; Lauria, A.; Almericom, A.M.; Leal, J.M.; Busto, N.; Garcia, B. DNA-binding of nickel (II), copper (II) and zinc (II) complexes: Structure–affinity relationships. Coord. Chem. Rev. 2013, 257, 2848–2862. [CrossRef]

45. Selvakumar, B.; Rajendiran, V.; Maheswari, P.U.; Stoeckli-Evans, H.; Palaniandavar, M. Structures, spectra, and DNA-binding properties of mixed ligand copper (II) complexes of iminodiacetic acid: The novel role of diimine co-ligands on DNA conformation and hydrolytic and oxidative double strand DNA cleavage. J. Inorg. Biochem. 2006, 100, 316–330. [CrossRef] [PubMed]

46. Busto, N.; Martínez-Alonso, M.; Leal, J.M.; Rodriguez, A.M.; Domínguez, F.; Acuña, M.I.; Espino, G.; Garcia, B. Monomer–Dimer Divergent Behavior toward DNA in a Half-Sandwich Ruthenium (II) Aqua Complex. Antiproliferative Biphasic Activity. Organometallics 2015, 34, 319–327. [CrossRef]

47. Peña-Morán, O.A.; Villarreal, M.L.; Álvarez-Berber, L.; Meneses-Acosta, A.; Rodríguez-López, V. Cytotoxicity, Post-Treatment Recovery, and Selectivity Analysis of Naturally Occurring Podophyllotoxins from Bursera fagaroides var. fagaroides on Breast Cancer Cell Lines. Molecules 2016, 21, 1013. [CrossRef]

48. Dudev, T.; Lim, C. Tetrahedral vs Octahedral Zinc Complexes with Ligands of Biological Interest: A DFT/CDM Study. J. Am. Chem. Soc. 2000, 122, 11146–11153. [CrossRef]